协和医学杂志2024，Vol.15Issue(2)：375-381,7.DOI:10.12290/xhyxzz.2023-0383
ADAM17在胃癌中的研究进展
Research Progress of ADAM17 in Gastric Cancer
杨梦娇 1袁浩 2郑亚 2王玉平 2郭庆红2
作者信息
- 1. 兰州大学第一临床医学院,兰州 730000||兰州大学第一医院消化科,兰州 730000||甘肃省消化疾病临床研究中心,兰州 730000
- 2. 兰州大学第一医院消化科,兰州 730000||甘肃省消化疾病临床研究中心,兰州 730000
- 折叠
摘要
Abstract
Gastric cancer is one of the most common malignant tumors in the world.Patients with gastric cancer are often treated by surgery,radiotherapy,chemotherapy or immunotherapy,but the clinical efficacy and prognosis are poor.As an important member of ADAMs family,a disintegrin and metalloprotease 17(ADAM17)is significantly more highly expressed in gastric cancer than in adjacent tissues.It participates in the occurrence and development of gastric cancer by mediating EGFR,TNF-α,TGF-β/Smad,Notch and Wnt,FoxM1-ADAM17 and EGFR/ERK/SP1.The high expression of ADAM17 is also closely related to the poor prognosis of gastric cancer,suggesting that ADAM17 can be used as a biological index to predict the develop-ment and prognosis of gastric cancer and has great potential to become a new therapeutic target for gastric canc-er.In this paper,the mechanism,treatment and prognosis of ADAM17 in the development of gastric cancer are reviewed,in order to provide new ideas for clinical diagnosis and treatment of gastric cancer.关键词
胃癌/去整合素-金属蛋白酶17/作用机制/靶向治疗/预后Key words
gastric cancer/ADAM17/mechanism of action/targeted therapy/prognosis分类
医药卫生引用本文复制引用
杨梦娇,袁浩,郑亚,王玉平,郭庆红..ADAM17在胃癌中的研究进展[J].协和医学杂志,2024,15(2):375-381,7.
